BC2059 (Discontinued)

• CAT Number: I004090
• CAS Number: 1227637-23-1
• Molecular Formula: C28H36N4O6S2
• Molecular Weight: 588.74
• Purity: ≥95%
• Synonyms: (9E,10E)-2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime
• Target: β-Catenin Inhibitor
• Solubility: Soluble in DMSO, not in water
• Storage: 2-8°C
• IUPAC Name: N-[3,6-bis[[(3R,5S)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine
• InChI: InChI=1S/C28H36N4O6S2/c1-17-9-18(2)14-31(13-17)39(35,36)21-5-7-23-25(11-21)28(30-34)26-12-22(6-8-24(26)27(23)29-33)40(37,38)32-15-19(3)10-20(4)16-32/h5-8,11-12,17-20,29,33H,9-10,13-16H2,1-4H3/t17-,18+,19-,20+
• InChIKey: OMWCXCBGEFHCTN-FGYAAKKASA-N
• SMILES: CC1CC(CN(C1)S(=O)(=O)C2=CC3=C(C=C2)C(=C4C=CC(=CC4=C3N=O)S(=O)(=O)N5CC(CC(C5)C)C)NO)C

Tegatrabetan (Cat No.:I004090), also known as BC2059, is a β-Catenin antagonist. Tegatrabetan (BC2059) disrupts the binding of β-catenin to scaffold protein transducin β-like 1 (TBL1) and proteasomal degradation and reduces the nuclear level of β-catenin.

Reference

1: Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C,  Zu Y, Iyer S, Bhalla KN. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leuke